Protein Production Strategy Could Accelerate Structure-Based Drug Discovery
Key Points
- Nuclera and University of Cambridge researchers obtained a 3.38 Å cryo-EM structure of an engineered human A2A receptor in four days, from gene assembly to sample preparation.
- The workflow combined cell-free protein synthesis, lipid nanodisc technology and cryo-EM, and successfully produced 12 additional GPCRs across Classes A, B and C.
- The approach could reduce a key bottleneck for difficult membrane protein targets in structure-based drug discovery.
A collaboration between Nuclera and researchers at the University of Cambridge has demonstrated a cell-free protein production method that could shorten the time required to obtain high-resolution structural data on difficult-to-produce drug targets. The study, published as a preprint on bioRxiv, describes a workflow that combines cell-free protein synthesis, proprietary lipid nanodisc technology and cryo-electron microscopy (cryo-EM) to analyze G protein-coupled receptors (GPCRs). Using the approach, the research team obtained a 3.38 Å resolution structure of an engineered human adenosine A2A receptor (A2AR) bound to an antagonist, completing the process from gene assembly to cryo-EM sample preparation in just four days.
The work addresses a persistent challenge in structural biology: producing sufficient quantities of stable, properly folded membrane proteins for detailed structural characterization. GPCRs represent an important class of therapeutic targets, but their complex structures and membrane-associated properties can make conventional expression, purification and stabilization processes time-consuming and difficult to optimize.
To streamline the process, the researchers combined Nuclera’s protein discovery platform with structural biology capabilities at the University of Cambridge’s Department of Biochemistry. The team used cell-free protein synthesis to evaluate different A2AR constructs across six lipid nanodisc conditions included in Nuclera’s GPCR nanodisc panel.
Following the initial screening, researchers selected one of the higher-yielding conditions for larger-scale production and subsequent purification. The resulting protein underwent quality assessment before being prepared for cryo-EM analysis. Structural data showed that the engineered receptor closely resembled a reference structure generated using conventional protein production methods.
The researchers also examined whether the approach could be extended to other members of the GPCR family. They successfully produced and purified 12 additional receptors representing Classes A, B and C. The group included six orphan GPCRs, a subset of receptors for which endogenous activating ligands have yet to be identified.
Protein quality was evaluated using fluorescence-detection size-exclusion chromatography (FSEC). The results indicated that the workflow could support the production of a broader range of GPCRs, potentially providing researchers with additional opportunities for structural characterization and biophysical studies.
Dr. Dimitri Chirgadze, cryo-EM Facility Manager in the University of Cambridge’s Department of Biochemistry, says obtaining suitable samples remains a significant obstacle in applying cryo-EM to complex membrane proteins. He noted that the study demonstrates how rapid, cell-free production can generate active proteins suitable for high-resolution structural investigation.
Dr. Michael Chen, Co-founder and Chief Scientific and Business oOficer at Nuclera, says the collaboration highlights the potential of integrating cell-free synthesis and nanodisc technology to improve access to challenging membrane protein targets. He added that the approach could help reduce the time and effort involved in preparing proteins for structural analysis, supporting future drug discovery research.
The findings suggest that combining rapid protein production with membrane protein stabilization technologies could help address an important bottleneck in structure-based drug discovery, particularly for targets that have historically been difficult to express and characterize.
Learn more at www.nuclera.com.
Total Page Views: 8

















